相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
Lisa Pleyer et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
Lars Bullinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
J. S. Welch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients 60 years old
Neha Gupta et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States
Bruno C. Medeiros et al.
ANNALS OF HEMATOLOGY (2015)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction
F. Ramos et al.
LEUKEMIA RESEARCH (2015)
Azacitidine in untreated acute myeloid leukemia: A report on 149 patients
Sylvain Thepot et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
Lisa Pleyer et al.
ANNALS OF HEMATOLOGY (2014)
Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
Felicetto Ferrara
HEMATOLOGICAL ONCOLOGY (2014)
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial
Steven D. Gore et al.
HAEMATOLOGICA (2013)
Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients
Lieke H. van der Helm et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts
L. H. van der Helm et al.
LEUKEMIA RESEARCH (2013)
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
Alfonso Quintas-Cardama et al.
BLOOD (2012)
Acute myeloid leukemia in the real world: why population-based registries are needed
Gunnar Juliusson et al.
BLOOD (2012)
Azacitidine for the treatment of patients with acute myeloid leukemia
Luca Maurillo et al.
CANCER (2012)
Survival for older patients with acute myeloid leukemia: a population-based study
Betul Oran et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Treatment of Unfit Patients With Acute Myeloid Leukemia: A Still Open Clinical Challenge
Felicetto Ferrara
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
Hagop Kantarjian et al.
BLOOD (2010)
Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study
Heiko Becker et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Superior Outcome With Hypomethylating Therapy in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome and Chromosome 5 and 7 Abnormalities
Farhad Ravandi et al.
CANCER (2009)
Outcomes and Quality of Care in Acute Myeloid Leukemia Over 40 Years
Shabbir M. H. Alibhai et al.
CANCER (2009)
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Bob Lowenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years:: Results from AMLSG trial AML HD98-B
Stefan Froehling et al.
BLOOD (2006)
Treatment of acute myelogenous leukemia with outpatient azacitidine
Nimit Sudan et al.
CANCER (2006)
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
Lewis R. Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
